MANKIND

Mankind Pharma Limited · NSE · INE634S01028 · F&O · lot 250 · 272 sessions on record

₹2,535.00▲ +31.20 · +1.3%from ₹2,503.80 the session before · 1 Oct 2026 close · NSE end of day

Open: ₹2,500.00
High: ₹2,535.00
Low: ₹2,476.10
Day's range: ₹592.4% of the previous close
VWAP: ₹2,504.81close +1.2% from it
Volume, shares: 4.3 L0.80× the 20-session average
Turnover, ₹ crore: 110
Trades: 32,00014 shares per trade
Previous close: ₹2,503.80+31.20 to the close
Price band, next session: ₹2,281.50 – ₹2,788.5010% either side of the close · dynamic, widened in 5% steps when hit

Day range100% of the way up

₹2,476.10₹2,535.00

52-week range85% of the way up

₹1,909.70 23 Mar₹2,642.00 29 Jul

−4.0% from the high · +33% from the low

The desk read · 1 Octexpiry 27 Oct · 26 days

long build-up

futures read

price +1.3% · OI +5.4%

−20.70

futures premium, ₹

−0.8% to spot ₹2,535.00

0.92

puts per call, by OI

by volume 0.66

2,500

max pain

−1.4% from the close

▲ +5.4%

futures OI on the day

+630 lots · 12,000 open

Long build-up into a 26-day expiry: futures OI +5.4% on a +1.3% day, the most call OI sits at 2,500, the most put OI at 2,300, max pain 2,500.

Futures and options

1 Oct close · lot 250 · NSE end of day

MANKIND futures closed at ₹2,514.30, −0.8% to spot, with 99% of open interest in the 27 Oct contract, and the 2,540 straddle prices a move of about ±13% by expiry.

Futures by expiryall 3 contracts NSE lists on the stock · basis against the spot close ₹2,535.00

Futures by expiry, basis against the spot close ₹2,535.00
Expiry	Close ₹	Basis ₹ · %	Annualised %	OI lots · on the day	Share of OI %	Contracts traded
27 Oct26 days	₹2,514.30	−20.70−0.8%	−11%	12,000▲ +5.5% · +620 lots	99	2,100
23 Nov53 days	₹2,514.10	−20.90−0.8%	−5.7%	120▲ +2.5% · +3.0 lots	1.0	45
29 Dec89 days	₹2,504.00	−31.00−1.2%	−5.0%	8.00.0% · 0.00 lots	0.07	0.00

1.1% of futures OI sits beyond the 27 Oct contract · 43 of 70 listed contracts traded · 7,500 option contracts changed hands

Options27 Oct expiry · 26 days

The 2,540 straddle closed at ₹318.65 (call 58.85 + put 259.80), pricing a move of about ±13% by the 27 Oct expiry. In the last 253 windows of 19 sessions, MANKIND moved more than that 15 times.

Call OI, lots: 2,9007.3 L shares
Put OI, lots: 2,7006.7 L shares
Puts per call, by OI: 0.92by volume 0.66
Max pain: 2,500−1.4% from the close
Contracts traded: 43 of 70listed for this expiry

Open interest by strike, lotstop three strikes each side

Calls

Strike

Puts

430

2,600

470

2,500

350

260

2,460

390

2,300

530

Open interest added on the day, lotsthree largest additions each side

Calls

Strike

Puts

+38

2,920

+22

2,760

+27

2,560

2,380

+34

2,300

+64

2,100

+12

Close ₹ · Nifty 50 rebased to the first close · futures open interest by the day's build-up126 sessions to 1 Oct · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

272 sessions on file · from 28 Aug

MANKIND close
Nifty 50, rebased
long build-up · price up, OI up
short build-up · price down, OI up
short covering · price up, OI down
long unwinding · price down, OI down

Session read · latest close: 1 Oct 2026
Close ₹ · day %: ₹2,535.00▲ +1.2% on the previous close
Against Nifty 50: Nifty −0.9%+2.1 pp difference on the day
Futures OI, lots: 12,000+630 lots · +5.4% on the day
The day's build-up: long build-upprice +1.2% · OI +5.4%
Against the averages: above 20 · above 5020-session ₹2,380.57 (+6.5%) · 50-session ₹2,417.34 (+4.9%)
Volume: 0.80×the previous 20 sessions · 4.3 L shares
Extremes on the day: none

The market after the news

close against the last close before each bulletin · Nifty 50 over the same sessions

After the last 4 bulletins, MANKIND closed higher five sessions later in 0 of 4.

Close after each bulletin on the day, one session later and five sessions later, with Nifty 50 and futures open interest
Bulletin	Day of the news	1 session later	5 sessions later	Futures OI on the day
20 MayMankind Pharma reports Q4 FY26 revenue growth of 12%	▼ −2.7%Nifty 0.0% · −2.7 pp	▼ −4.0%Nifty +0.3% · −4.3 pp	▼ −8.1%Nifty −0.5% · −7.6 pp	▼ −10.8%long unwinding
19 MarMankind Pharma acquires Rivotril brand from Roche	▼ −4.9%Nifty −3.3% · −1.6 pp	▼ −4.9%Nifty −2.8% · −2.1 pp	▼ −3.1%Nifty −4.0% · +1.0 pp	▲ +2.9%short build-up
18 MarMankind Pharma acquires Rivotril brand from Roche	▼ −4.9%Nifty −3.3% · −1.6 pp	▼ −4.9%Nifty −2.8% · −2.1 pp	▼ −3.1%Nifty −4.0% · +1.0 pp	▲ +2.9%short build-up
4 FebBajaj Finance profit declines 6%, Mankind Pharma revenue up 12%	▼ −0.4%Nifty −0.5% · +0.1 pp	▼ −1.4%Nifty −0.3% · −1.1 pp	▼ −0.5%Nifty +0.1% · −0.6 pp	▲ +1.7%short build-up

4 of 4 bulletins

Quarterly results

consolidated · latest filed 30 Jul, 08:15 pm IST · NSE filings

Revenue ₹4,031 cr, +13% on a year earlier; profit ₹574 cr, +29% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidated₹ crore as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, Nifty 50 over the same session

Quarterly results of MANKIND on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹	Market on the day
Jun 2026filed 30 Jul	₹4,031 cr	▲ +13%	₹574 cr	▲ +29%	13.74	▼ −4.1%Nifty +0.3% · −4.4 pp
Mar 2026filed 19 May · audited	₹3,443 cr	▼ −72%	₹559 cr	▼ −72%	13.41	▲ +3.7%Nifty +0.2% · +3.5 pp
Dec 2025filed 3 Feb	₹3,567 cr	▲ +10%	₹414 cr	▲ +7.6%	9.89	▼ −3.4%Nifty +0.2% · −3.6 pp
Sept 2025filed 6 Nov	₹3,697 cr	▲ +20%	₹520 cr	▼ −21%	12.38	▼ −2.0%Nifty −0.1% · −2.0 pp
Jun 2025filed 31 Jul	₹3,570 cr	▲ +23%	₹445 cr	▼ −18%	10.60	0.0%Nifty −0.8% · +0.8 pp
Mar 2025filed 21 May · audited	₹12,207 cr	▲ +400%	₹2,011 cr	▲ +320%	49.19	▼ −3.6%Nifty −0.8% · −2.8 pp
Dec 2024filed 24 Jan	₹3,230 cr	▲ +24%	₹385 cr	▼ −16%	9.44	▼ −4.9%Nifty −0.5% · −4.4 pp
Sept 2024filed 5 Nov	₹3,077 cr	▲ +14%	₹659 cr	▲ +29%	16.28	▲ +1.3%Nifty +1.1% · +0.1 pp

By financial yearApril to March · each year the sum of its four quarters as filed, consolidated · EPS summed across the quarters · only complete years

Financial-year results of MANKIND on the consolidated basis, summed from the quarters filed
Year	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹
FY26to Mar 2026	₹14,278 cr	▼ −33%	₹1,938 cr	▼ −46%	46.28
FY25to Mar 2025	₹21,407 cr	▲ +110%	₹3,598 cr	▲ +85%	88.28
FY24to Mar 2024	₹10,335 cr	—	₹1,942 cr	—	47.68

Fundamentals

consolidated · filings to Jun 2026 · close ₹2,535.00 on 1 Oct

MANKIND trades at 51 times trailing earnings against 38 for its industry, 6.3 times book value, revenue −33% over twelve months, market cap ₹1,00,000 cr.

Valuationarithmetic on filings and the close · each cell names what it rests on · — where an input is missing

Market cap: ₹1,00,000 cron 1 Oct · free float ₹29,000 cr
Price to earnings: 51consolidated · four quarters to Jun 2026 · industry 38
Trailing EPS: ₹49.42diluted · consolidated · four quarters to Jun 2026
Price to book: 6.3consolidated · balance sheet to Mar 2026
Book value a share: ₹400.95consolidated · balance sheet to Mar 2026 · over NSE's share count
Debt to equity: 0.38borrowings over equity · consolidated · balance sheet to Mar 2026
Return on equity: 13%trailing profit over average equity · consolidated
Dividend yield: —no dividend with an ex-date in 365 days
Face value: ₹1a share
Shares outstanding: 41 cron 1 Oct

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: ₹14,738 crfour quarters to Jun 2026
Revenue growth, 12 months: ▼ −33%against the twelve months before
Revenue 2-year CAGR: ▲ +18%trailing twelve months against the twelve months 2 years earlier · consolidated
Profit, trailing 12 months: ₹2,068 crfour quarters to Jun 2026
Profit growth, 12 months: ▼ −41%against the twelve months before
Profit 2-year CAGR: ▲ +1.9%trailing twelve months against the twelve months 2 years earlier · consolidated

PeersBSE sub-group Pharmaceuticals · F&O stocks with filings on record · industry P/E 38, market caps over trailing profit of 13 stocks

Stocks in the BSE sub-group Pharmaceuticals with market cap, price to earnings and price to book
Stock	Market cap ₹	P/E	P/B	Close ₹
SUNPHARMASun Pharmaceutical Industries Limited	4,30,000 cron 1 Oct	36consolidated	5.2	₹1,801.00
DIVISLABDivi's Laboratories Limited	2,50,000 cron 1 Oct	52consolidated	15	₹9,249.00
TORNTPHARMTorrent Pharmaceuticals Limited	1,80,000 cron 1 Oct	76consolidated	10	₹4,767.30
ZYDUSLIFEZydus Lifesciences Limited	1,10,000 cron 1 Oct	26consolidated	3.9	₹1,145.70
CIPLACipla Limited	1,10,000 cron 1 Oct	32consolidated	3.1	₹1,344.00
LAURUSLABSLaurus Labs Limited	1,10,000 cron 1 Oct	85consolidated	20	₹1,984.00
MANKINDMankind Pharma Limited	1,00,000 cron 1 Oct	51consolidated	6.3	₹2,535.00
DRREDDYDr. Reddy's Laboratories Limited	1,00,000 cron 1 Oct	31consolidated	2.6	₹1,206.20
AUROPHARMAAurobindo Pharma Limited	96,000 cron 1 Oct	26consolidated	2.5	₹1,676.80
LUPINLupin Limited	93,000 cron 1 Oct	17consolidated	4.1	₹2,031.20
GLENMARKGlenmark Pharmaceuticals Limited	66,000 cron 1 Oct	37consolidated	6.3	₹2,331.00
ALKEMAlkem Laboratories Limited	62,000 cron 1 Oct	29consolidated	4.3	₹5,220.00
BIOCONBiocon Limited	60,000 cron 1 Oct	110consolidated	1.6	₹370.70
ABBOTINDIAAbbott India Limited	57,000 cron 1 Oct	—	—	₹26,840.00
IPCALABIPCA Laboratories Limited	49,000 cron 1 Oct	—	5.2	₹1,943.20
GLANDGland Pharma Limited	47,000 cron 1 Oct	—	4.6	₹2,874.40
GLAXOGlaxoSmithKline Pharmaceuticals Limited	47,000 cron 1 Oct	—	21	₹2,771.10
AJANTPHARMAjanta Pharma Limited	45,000 cron 1 Oct	—	9.9	₹3,581.00
EMCUREEmcure Pharmaceuticals Limited	37,000 cron 1 Oct	—	7.4	₹1,944.60
WOCKPHARMAWockhardt Limited	34,000 cron 1 Oct	—	6.4	₹2,083.90
SAILIFESai Life Sciences Limited	33,000 cron 1 Oct	—	13	₹1,541.20
NEULANDLABNeuland Laboratories Limited	28,000 cron 1 Oct	—	15	₹21,505.00
RUBICONRubicon Research Limited	27,000 cron 1 Oct	—	21	₹1,630.90
PPLPHARMAPiramal Pharma Limited	26,000 cron 1 Oct	—	3.2	₹197.95
ACUTAASAcutaas Chemicals Limited	26,000 cron 1 Oct	—	15	₹3,196.50
SHILPAMEDShilpa Medicare Limited	21,000 cron 1 Oct	—	8.0	₹1,064.10
GRANULESGranules India Limited	20,000 cron 1 Oct	—	4.0	₹821.75
CAPLIPOINTCaplin Point Laboratories Limited	20,000 cron 1 Oct	—	5.5	₹2,631.90
PFIZERPfizer Limited	18,000 cron 1 Oct	—	4.2	₹3,858.90
ONESOURCEOnesource Specialty Pharma Limited	17,000 cron 1 Oct	—	3.0	₹1,508.00
COHANCECohance Lifesciences Limited	17,000 cron 1 Oct	—	4.3	₹451.30
ALIVUSAlivus Life Sciences Limited	17,000 cron 1 Oct	—	5.1	₹1,374.20
ERISEris Lifesciences Limited	16,000 cron 1 Oct	—	4.2	₹1,189.80
NATCOPHARMNatco Pharma Limited	16,000 cron 1 Oct	—	1.8	₹821.30
APLLTDAlembic Pharmaceuticals Limited	16,000 cron 1 Oct	—	2.8	₹815.25
JUBLPHARMAJubilant Pharmova Limited	16,000 cron 1 Oct	—	2.2	₹999.30
ASTRAZENAstraZeneca Pharma India Limited	15,000 cron 1 Oct	—	17	₹6,031.00
MARKSANSMarksans Pharma Limited	15,000 cron 1 Oct	—	4.8	₹325.60
CONCORDBIOConcord Biotech Limited	14,000 cron 1 Oct	—	7.1	₹1,374.10
AKUMSAkums Drugs and Pharmaceuticals Limited	13,000 cron 1 Oct	—	3.8	₹813.10
CORONACORONA Remedies Limited	12,000 cron 1 Oct	—	17	₹2,029.40
BLUEJETBlue Jet Healthcare Limited	10,000 cron 1 Oct	—	7.5	₹541.80
VIYASHViyash Scientific Limited	10,000 cron 1 Oct	—	3.3	₹231.75
STARStrides Pharma Science Limited	10,000 cron 1 Oct	—	3.2	₹1,084.80
PGHLProcter & Gamble Health Limited	8,900 cron 1 Oct	—	17	₹5,360.00
AARTIPHARMAarti Pharmalabs Limited	8,800 cron 1 Oct	—	4.1	₹968.50
SANOFICONRSanofi Consumer Healthcare India Limited	8,700 cron 1 Oct	—	25	₹3,787.20
SYMBIOTECSymbiotec Pharmalab Limited	7,700 cron 1 Oct	—	—	₹1,198.00
SUPRIYASupriya Lifescience Limited	7,500 cron 1 Oct	—	6.3	₹931.00
MOREPENLABMorepen Laboratories Limited	7,300 cron 1 Oct	—	5.9	₹133.70
SANOFISanofi India Limited	7,000 cron 1 Oct	—	8.5	₹3,037.40
INNOVACAPInnova Captab Limited	6,700 cron 1 Oct	—	6.1	₹1,168.00
SPARCSun Pharma Advanced Research Company Limited	6,300 cron 1 Oct	—	4.7	₹194.15
SENORESSenores Pharmaceuticals Limited	6,200 cron 1 Oct	—	6.4	₹1,349.60
IOLCPIOL Chemicals and Pharmaceuticals Limited	6,100 cron 1 Oct	—	3.4	₹209.40
ORCHPHARMAOrchid Pharma Limited	5,900 cron 1 Oct	—	4.6	₹990.00
FDCFDC Limited	5,500 cron 1 Oct	—	2.2	₹335.90
GUJTHEMGujarat Themis Biosyn Limited	5,000 cron 1 Oct	—	—	₹381.80
NOVARTINDNovartis India Limited	4,900 cron 1 Oct	—	—	₹1,965.00
RPGLIFERPG Life Sciences Limited	4,800 cron 1 Oct	—	8.0	₹2,930.70
SMSPHARMASMS Pharmaceuticals Limited	4,400 cron 1 Oct	—	5.6	₹471.30
GUFICBIOGufic Biosciences Limited	4,200 cron 1 Oct	—	6.3	₹418.40
AARTIDRUGSAarti Drugs Limited	3,800 cron 1 Oct	—	2.5	₹421.00
UNICHEMLABUnichem Laboratories Limited	3,800 cron 1 Oct	—	1.4	₹535.05
KPLKwality Pharmaceuticals Limited	3,700 cron 1 Oct	—	—	₹3,564.40
SOLARASolara Active Pharma Sciences Limited	3,400 cron 1 Oct	—	2.7	₹714.85
INDSWFTLABInd-Swift Laboratories Limited	3,400 cron 1 Oct	—	2.5	₹395.15
SHUKRAPHARShukra Pharmaceuticals Limited	2,700 cron 1 Oct	—	—	₹61.80
HIKALHikal Limited	2,700 cron 1 Oct	—	2.2	₹218.15
VENUSREMVenus Remedies Limited	2,400 cron 1 Oct	—	3.6	₹1,796.70
DCALDishman Carbogen Amcis Limited	2,400 cron 1 Oct	—	0.35	₹150.35
INDOCOIndoco Remedies Limited	2,300 cron 1 Oct	—	2.5	₹251.75
SAIPARENTSai Parenterals Limited	2,300 cron 1 Oct	—	4.7	₹523.65
SYNCOMFSyncom Formulations (India) Limited	2,300 cron 1 Oct	—	5.4	₹23.95
FREDUNFredun Pharmaceuticals Limited	2,200 cron 1 Oct	—	—	₹1,355.20
WINDLASWindlas Biotech Limited	2,200 cron 1 Oct	—	—	₹1,082.40
PANACEABIOPanacea Biotec Limited	2,200 cron 1 Oct	—	2.6	₹359.05
HESTERBIOHester Biosciences Limited	1,800 cron 1 Oct	—	4.9	₹2,126.80
NGLFINENGL Fine-Chem Limited	1,800 cron 1 Oct	—	5.5	₹2,924.00
AHCLAnlon Healthcare Limited	1,700 cron 1 Oct	—	6.8	₹32.85
FERMENTAFermenta Biotech Limited	1,600 cron 1 Oct	—	—	₹553.25
JAGSNPHARMJagsonpal Pharmaceuticals Limited	1,500 cron 1 Oct	—	5.5	₹231.75
AMRUTANJANAmrutanjan Health Care Limited	1,500 cron 1 Oct	—	4.0	₹513.20
KOPRANKopran Limited	1,400 cron 1 Oct	—	2.6	₹282.05
BPLPHARMABharat Parenterals Limited	1,200 cron 1 Oct	—	—	₹1,720.40
LINCOLNLincoln Pharmaceuticals Limited	1,200 cron 1 Oct	—	1.5	₹582.05
BAJAJHCAREBajaj Healthcare Limited	1,100 cron 1 Oct	—	2.0	₹322.95
SIGACHISigachi Industries Limited	1,100 cron 1 Oct	—	2.0	₹28.35
THEMISMEDThemis Medicare Limited	1,000 cron 1 Oct	—	2.6	₹113.20
SGRLShree Ganesh Remedies Limited	890 cron 1 Oct	—	—	₹694.25
ANUHPHRAnuh Pharma Limited	860 cron 1 Oct	—	2.4	₹85.85
ZIMLABZim Laboratories Limited	740 cron 1 Oct	—	2.5	₹137.00
WANBURYWanbury Limited	690 cron 1 Oct	—	4.8	₹198.00
ALBERTDAVDAlbert David Limited	490 cron 1 Oct	—	1.3	₹856.70
MEDICAMEQMedicamen Biotech Limited	470 cron 17 Sept	—	1.7	₹346.30
HALEOSLABSHALEOS LABS LIMITED	450 cron 1 Oct	—	2.0	₹1,490.00
JENBURPHJenburkt Pharmaceuticals Limited	400 cron 1 Oct	—	—	₹915.25
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	290 cron 1 Oct	—	2.0	₹103.85
NECLIFENectar Lifesciences Limited	200 cron 1 Oct	—	0.34	₹10.25
MEDICOMedico Remedies Limited	180 cron 1 Oct	—	2.4	₹21.85
BALPHARMABal Pharma Limited	170 cron 1 Oct	—	2.0	₹105.75
BROOKSBrooks Laboratories Limited	160 cron 1 Oct	—	1.3	₹54.80
KREBSBIOKrebs Biochemicals and Industries Limited	150 cron 1 Oct	—	—	₹68.05
PARNAXLABParnax Lab Limited	130 cron 1 Oct	—	—	₹113.15
ALPAAlpa Laboratories Limited	120 cron 1 Oct	—	0.67	₹59.25
MAKERSLMakers Laboratories Limited	110 cron 1 Oct	—	—	₹183.50
SUNLOCSunil Healthcare Limited	72 cron 1 Oct	—	—	₹70.10
VINEETLABVineet Laboratories Limited	69 cron 1 Oct	—	1.5	₹35.90
BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited	48 cron 1 Oct	—	2.2	₹29.30
MANGALAMMangalam Drugs And Organics Limited	46 cron 1 Oct	—	0.45	₹29.15
MEDICAPQMedi Caps Limited	31 cron 17 Sept	—	—	₹24.80
ORTINGLOBEORTIN GLOBAL LIMITED	12 cron 1 Oct	—	9.5	₹14.50
AMANTAAmanta Healthcare Limited	—	—	—	—
AMBALALSAAmbalal Sarabhai Enterprises Limited	—	—	—	—
BAFNAPHBafna Pharmaceuticals Limited	—	—	—	—
BLISSGVSBliss GVS Pharma Limited	—	—	—	—
KILITCHKilitch Drugs (India) Limited	—	—	—	—
LASALasa Supergenerics Limited	—	—	—	—
LYKALABSLyka Labs Limited	—	—	—	—
NATCAPSUQNatural Capsules Limited	—	—	—	—
VALIANTLABValiant Laboratories Limited	—	—	—	—
VIVIMEDLABVivimed Labs Limited	—	—	—	—

Shareholding

quarter to 30 Jun · none pledged · NSE filings

Promoters hold 72.6%, foreign portfolio investors 9.4%, mutual funds 10.9% and insurance companies 1.5%, as filed for the quarter to 30 Jun.

72.6%9.4%10.9%

By category, last 5 quarterspercent of shares · beneath each figure, the change in percentage points against the previous quarter on file

Shareholding of MANKIND by category over the last 5 quarters with the change against the previous quarter
Category	30 Jun	31 Mar	31 Dec	30 Sept	30 Jun
Promoters	72.63▼ −0.03 pp	72.660.00 pp	72.66▼ −0.01 pp	72.67▼ −0.01 pp	72.68
Foreign portfolio investors	9.45▼ −0.79 pp	10.24▼ −1.10 pp	11.34▼ −1.49 pp	12.83▼ −0.24 pp	13.07
Mutual funds	10.87▲ +0.51 pp	10.36▲ +1.06 pp	9.30▲ +1.52 pp	7.78▲ +0.44 pp	7.34
Insurance companies	1.54▲ +0.40 pp	1.14▲ +0.02 pp	1.12▼ −0.65 pp	1.77▼ −0.47 pp	2.24
Banks and financial institutions	2.98▲ +0.02 pp	2.96▲ +0.12 pp	2.84▲ +0.48 pp	2.36▲ +0.44 pp	1.92
Individual investors	1.34▼ −0.11 pp	1.45▼ −0.13 pp	1.58▲ +0.16 pp	1.42▼ −0.16 pp	1.58
Bodies corporate	1.04▼ −0.03 pp	1.07▼ −0.01 pp	1.08▲ +0.01 pp	1.070.00 pp	1.07
Others	0.15▲ +0.03 pp	0.12▲ +0.03 pp	0.09▼ −0.01 pp	0.100.00 pp	0.10

Corporate actions

NSE and BSE records

Nothing upcoming on record; the last was a dividend of ₹1.00 a share, ex-date 8 Aug 2025.

Actionsex-dates · upcoming first, then the last eight · dividends in rupees a share, bonus and split as ratios

Corporate actions of MANKIND, upcoming first, then the most recent
Ex-date	Action	Amount or ratio	Record date	Source
recent
8 Aug 2025	dividend	₹1.00	8 Aug 2025	BSE

Calendaras notified to the exchange

Next results: —no board meeting notified yet
Dividends in 365 days: —a share · ex-dates inside the year
Last dividend: ₹1.00ex-date 8 Aug 2025

Price history

272 sessions on record · to 1 Oct · NSE end of day

MANKIND is +6.0% over 20 sessions against Nifty's −6.2%, 4.0% below its 52-week high, realised volatility 34% annualised.

Returns against Nifty 50longest window first · Nifty 50 over the same sessions

Returns of the stock and Nifty 50 over six windows, longest first
Window	From ₹	MANKIND %	Nifty 50 %	Difference pp
250 sessionssince 26 Sept	₹2,482.86	▲ +2.1%	▼ −9.1%	+11
120 sessionssince 9 Apr	₹2,054.13	▲ +23%	▼ −5.7%	+29
60 sessionssince 8 Jul	₹2,491.16	▲ +1.8%	▼ −6.1%	+7.9
20 sessionssince 2 Sept	₹2,391.51	▲ +6.0%	▼ −6.2%	+12
5 sessionssince 24 Sept	₹2,500.00	▲ +1.4%	▼ −2.8%	+4.2
1 sessionsince 30 Sept	₹2,503.70	▲ +1.3%	▼ −0.88%	+2.1

Averages of the closeclose against each average

5-session average: ₹2,498.86close +1.4% from it
20-session average: ₹2,380.57close +6.5% from it
50-session average: ₹2,417.34close +4.9% from it
200-session average: ₹2,293.93close +11% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: ₹682.7% of the close
Average day's range, 20: ₹662.6% of the close
Volume against 20 sessions: 0.80×4.3 L vs 5.4 L average

Volatility and co-movement with Nifty 50annualised from daily log returns · counts share one denominator per cell

Realised volatility, 20: 34%≈ ±2.1% a session · moved more than that on 3 of 20
Realised volatility, 60: 27%≈ ±1.7% a session · moved more than that on 16 of 60
Realised volatility, 250: 26%≈ ±1.7% a session · moved more than that on 67 of 250
Beta to Nifty, 60: -0.19moved with Nifty on 22 of 60 sessions
Beta to Nifty, 250: 0.64moved with Nifty on 147 of 250 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 9 up · 11 downof 20
Last 60 sessions: 27 up · 33 downof 60
Last 250 sessions: 114 up · 136 downof 250
Best session, 250: ▲ +6.0%21 Sept
Worst session, 250: ▼ −4.9%19 Mar

Mankind Pharma Limited is in 18 NSE indices

all 18 indices

4 bulletins on MANKIND

latest 20 May 2026

Beats in the coverage

Pharma3

Often mentioned with

BAJFINANCE1

May 2026

20 May Mankind Pharma reports Q4 FY26 revenue growth of 12%Mankind Pharma reported Q4 FY26 revenue growth of 11.8% YoY to ₹3,443 cr, with EBITDA rising 36.1% to ₹930 cr. EBITDA margin improved to 27%, driven by strong domestic performance despite a slight dip in net profit to ₹420.8 cr.Medium

March 2026

19 Mar Mankind Pharma acquires Rivotril brand from RocheMankind Pharma has acquired the Rivotril brand from Roche for the Indian market, enhancing its CNS therapy segment. This move aligns with Mankind's focus on chronic therapies, expanding its portfolio and specialist engagement.Medium 18 Mar Mankind Pharma acquires Rivotril brand from RocheMankind Pharma has acquired the Rivotril brand from Roche, securing exclusive rights for the Indian market. This acquisition strengthens Mankind's position in CNS therapies and aligns with its focus on expanding chronic therapies, which are growing in importance for the company.Medium

February 2026

4 Feb Bajaj Finance profit declines 6%, Mankind Pharma revenue up 12%Bajaj Finance reported a 6% decline in Q3 profit, while Mankind Pharma's revenue rose 12%. These results come amid a busy earnings season with over 100 companies reporting today, influencing market dynamics.Medium

About Mankind Pharma Limited

exchange masters as of 18 Sept 2026 · classification by BSE

Company: Mankind Pharma Limited
Exchange: NSE · BSE 543904, group A
Listed on NSE: 9 May 2023
Classification: Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Index: BSE 200
Face value: ₹1 a share
ISIN: INE634S01028
Sessions on record: 272
Price source: NSE UDiFF bhavcopy · end of day · delayed
Filings: NSE and BSE public disclosures · results, shareholding and corporate actions as filed
Computed: 1 Oct, 09:19 pm IST
Bulletins: 4 · written by the desk · not a recommendation

OI Charts is not a SEBI-registered investment adviser or research analyst. Prices, open interest, filings and the desk read are exchange data and arithmetic on it, not a basis for any investment decision.